Study on the Efficacy of Spinal Cord Stimulation in Patients With Severe Refractory Primary or Se… (NCT07571733) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Study on the Efficacy of Spinal Cord Stimulation in Patients With Severe Refractory Primary or Secondary RLS
Switzerland15 participantsStarted 2026-06-01
Plain-language summary
A Double-Blind Randomized Controlled Crossover Study to compare the short-efficacy of Burst-SCS with Sham Stimulation, in patients with severe to very severe RLS refractory or intolerant to standard available treatments and/or patients in augmentation, with a two-period-alternating treatment design.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female (all sexes) aged 18 years or older, inclusive;
* Diagnosis of primary or secondary RLS;
* Severe to very severe RLS defined as IRLS-RS score \> 20;
* Duration of RSL symptoms ≥ 6 months;
* Insufficient symptom control achieved by and/or intolerance to established mono- or combination therapy of standard pharmacological treatment incl. patients in augmentation;
* Stable pharmacologic therapy for RLS for at least 1 month;
* A stable pattern of neurological symptoms;
* Patients who are legally competent and able to understand the nature, scope and aim of the clinical trial;
* Signed informed subject consent form
Exclusion Criteria:
* Known hypersensitivity or allergy to the materials of the device;
* Concomitant use of psychoactive-drugs (e.g. benzodiazepines, antidepressants; wash-out period: at least 7 days or longer depending on half-life);
* Co-morbid sleep disorders influencing sleep structure and nocturnal motor pattern (e.g. Narcolepsy, REM sleep behaviour disorder etc.);
* Coagulopathy or oral anticoagulant therapy (except low-dose acetylsalicylic acid) in conditions that do not allow for a temporary discontinuation;
* Active infection, systemic or localized;
* Known immune deficiency;
* Presence of spinal cord or peripheral nerve stimulators;
* Any disease process or condition that may make the effect of the treatment difficult to evaluate (e.g. cancer with low life expectancy);
* Severe psychiatric disorders (including substance…
What they're measuring
1
RLS symptom severity
Timeframe: From baseline of the treatment phase to the end of the 2.5 months treatment phase